BIO-TECHNE DECLARES DIVIDEND
Future cash dividends will be considered by the board on a quarterly basis, as applicable.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) declared a quarterly dividend of $0.08 per share, payable November 23, 2026, subject to a transaction-closing condition.
The dividend covers the quarter ended September 30, 2026, for common shareholders of record at the close of business November 13, 2026. Payment depends on the previously announced transaction with Merck KGaA, Darmstadt, Germany not closing on or before the close of business November 13, 2026.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Dividend payment is conditional on the Merck KGaA transaction not closing by close of business November 13, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated over
Forward-Looking Statements
Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act, including statements regarding the payment and timing of the quarterly dividend and the pending acquisition of Bio-Techne by Merck KGaA, Darmstadt, Germany. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including: the timing of completion of the pending transaction, including whether it is completed on or before the dividend record date; the satisfaction of the conditions to the pending transaction, including receipt of required shareholder and regulatory approvals; the effect of the announcement or pendency of the transaction on Bio-Techne's business, operations and stock price; and the other factors described under "Risk Factors" in Bio-Techne's Annual Report on Form 10-K for the fiscal year ended June 30, 2026 and its subsequent Quarterly Reports on Form 10-Q and other filings with the U.S. Securities and Exchange Commission.
For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.
|
Contact: |
David Clair, Vice President, Investor Relations |
|
|
|
|
|
612-656-4416 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-declares-dividend-302928623.html
SOURCE Bio-Techne Corporation
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much is Bio-Techne's dividend and when will it be paid?
Bio-Techne declared $0.08 per share, payable November 23, 2026, to common shareholders of record at the close of business November 13, 2026. Payment is conditional on its previously announced transaction with Merck KGaA, Darmstadt, Germany not closing on or before the close of business November 13, 2026.